Endocrine modifications and interventions during critical illness

Proceedings of the Nutrition Society

Volumn 63, Issue 3, 2004, Pages 443-450

  Weekers, Frank ^a   Van Den Berghe, Greet ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Endocrinology; Metabolism; Stress

Indexed keywords

ANABOLIC AGENT; HYPOPHYSIS HORMONE;

ADENOHYPOPHYSIS; CACHEXIA; CHRONIC DISEASE; CONFERENCE PAPER; CRITICAL ILLNESS; HORMONAL REGULATION; HORMONE RELEASE; HORMONE SENSITIVITY; HUMAN; HYPERMETABOLISM; HYPOTHALAMUS; LEAN BODY WEIGHT; STRESS;

ACUTE DISEASE; CHRONIC DISEASE; CRITICAL ILLNESS; ENDOCRINE SYSTEM; ENERGY METABOLISM; HUMANS; STRESS;

EID: 4344570685     PISSN: 00296651     EISSN: None     Source Type: Journal    
DOI: 10.1079/PNS2004373     Document Type: Conference Paper

References (52)

1. Angele MK, Ayala A, Cioffi WG, Bland KI & Chaudry IH (1998) Testosterone: the culprit for producing splenocyte immune depression after trauma hemorrhage. American Journal of Physiology 274, C1530-C1536.
2. Bacci V, Schussler GC & Kaplan TB (1982) The relationship between serum triiodothyronine and thyrotropin during systemic illness. Journal of Clinical Endocrinology and Metabolism 54, 1229-1235.
3. Berman R, Harrison L, Pearlstone D, Burst M & Brennan M (1999) Growth hormone, alone and in combination with insulin, increases whole body and skeletal muscle protein kinetics in cancer patients after surgery. Annals of Surgery 229, 1-10.
4. Binnerts A, Swart G, Wilson J, Hoogerbrugge N, Pols H, Birkenhager J & Lamberts S (1992) The effects of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition. Clinical Endocrinology 37, 79-87.
5. Costa C, Solanes G, Visa J & Bosch F (1998) Transgenic rabbits overexpressing growth hormone develop acromegaly and diabetes mellitus. FASEB Journal 12, 1455-1460.
6. Dahn MS, Lange MP & Jacobs LA (1988) Insulin-like growth factor 1 production is inhibited in human sepsis. Archives of Surgery 123, 1409-1414.
7. Defalque D, Brandt N, Ketelslegers J & Thissen J (1999) GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. American Journal of Physiology 276, E565-E572.
8. Demling RH (1999) Comparison of the anabolic effects and complications of human growth hormone and the testosterone analog, oxandrolone, after severe burn injury. Burns 25, 215-221.
9. Ferrando AA, Sheffield-Moore M, Wolf SE, Herndon DN & Wolfe RR (2001) Testosterone administration in severe burns ameliorates muscle catabolism. Critical Care Medicine 10, 1936-1942.
10. Fliers E, Wiersinga WM & Swaab DF (1998) Physiological and pathophysiological aspects of thyrotropin-releasing hormone gene expression in the human hypothalamus. Thyroid 8, 921-928.
11. Gamrin L, Andersson K, Hultman E, Nilsson E, Essen P & Wernerman J (1997) Longitudinal changes of biochemical parameters in muscle during critical illness. Metabolism 46, 756-762.
12. Gamrin L, Essen P, Hultman E, McNurlan M, Garlick P & Wernerman J (2000) Protein sparing effect in skeletal muscle of growth hormone treatment in critically ill patients. Annals of Surgery 231, 577-586.
13. Gardner DF, Kaplan MM, Stanley CA & Utiger RD (1979) Effect of tri-iodothyronine replacement on the metabolic and pituitary responses to starvation. New England Journal of Medicine 300, 579-584.
14. Gilpin DA, Barrow RE, Rutan RL, Broemeling L & Herndon DN (1994) Recombinant human growth hormone accelerates wound healing in children with large cutaneous burns. Annals of Surgery 220, 19-24.
15. Hart DW, Wolf SE, Zhang XJ, Chinkes DL, Buffalo MC, Matin SI, DebRoy MA, Wolfe RR & Herndon DN (2001) Efficacy of a high-carbohydrate diet in catabolic illness. Critical Care Medicine 29, 1318-1324.
16. Hermansson M, Wickelgren RB, Hammarqvist F, Bjarnason R, Wennstrom I, Wernerman J, Carlsson B & Carlsson LM (1997) Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: demonstration of reduced expression after elective surgery. Journal of Clinical Endocrinology and Metabolism 82, 421-428.
17. Herndon DN, Hart DW, Wolf SE, Chinkes DL & Wolfe RR (2001) Reversal of catabolism by beta-blockade after severe burns. New England Journal of Medicine 345, 122-129.
18. Heyland DK, MacDonald S, Keefe L & Drover JW (1998) Total parenteral nutrition in the critically ill patient: a meta-analysis. Journal of the American Medical Association 280, 2013-2019.
19. Hillier TA, Fryburg DA, Jahn LA & Barrett EJ (1998) Extreme hyperinsulinemia unmasks insulin's effect to stimulate protein synthesis in the human forearm. American Journal of Physiology 274, E1067-E1074.
20. Keller U & Miles J (1991) Growth hormone and lipids. Hormone Research 36, 36-40.
21. Koea J, Breier B, Douglas R, Gluckman P & Shaw J (1996) Anabolic and cardiovascular effects of recombinant human growth hormone in surgical patients with sepsis. British Journal of Surgery 83, 196-202.
22. Liao W, Rudling M & Angelin B (1996) Growth hormone potentiates the in vivo biological activities of endotoxin in the rat. European Journal of Clinical Investigation 26, 254-258.
23. Liu B, Miyata S, Kojima A, Kusunoki H, Suzuki K & Kasuga M (1999) Low phagocytic activity of resident peritoneal macrophages in diabetic mice: relevance to the formation of advanced glycation end procucts. Diabetes 48, 2074-2082.
24. Mjaaland M, Unneberg K, Larsson J, Nilsson L & Revhaug A (1993) Growth hormone after abdominal surgery attenuated forearm glutamine, alanine, 3-methylhistidine, and total amino acid efflux in patients receiving total parenteral nutrition. Annals of Surgery 217, 413-422.
25. Moller J, Jorgensen J, Moller N, Christiansen J & Weeke J (1992) Effects of growth hormone administration on fuel oxidation and thyroid function in normal man. Metabolism 41, 728-731.
26. O'Leary M, Fergusson C, Rennie M, Hinds C, Coakley J & Preedy V (2002) Effect of growth hormone on muscle and liver protein synthesis in septic rats receiving glutamine-enriched parenteral nutrition. Critical Care Medicine 30, 1099-1105.
27. Peeters RP, Wouters PJ, Kaptein E, van Toor H, Visser TJ & Van den Berghe G (2003) Reduced activation and increased inactivation of thyroid hormone in tissues of critically ill patients. Journal of Clinical Endocrinology and Metabolism 88, 3202-3211.
28. Rivier C & Vale W (1983) Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature 305, 325-327.
29. Robin P, Arain I, Phuangsab A, Holian O, Roccaforte P & Barrett JA (1989) Intravenous fat emulsion acutely suppresses neutrophil chemiluminescence. Journal of Parenteral and Enteral Nutrition 13, 608-613.
30. Ross R, Miell J, Freeman E, Jones J, Matthews D, Preece M & Buchanan C (1991) Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin-like growth factor-I. Clinical Endocrinology 35, 47-54.
31. Ross RJ, Rodriguez-Arnao J, Bentham J & Coakley JH (1993) The role of insulin, growth hormone and IGF-I as anabolic agents in the critically ill. Intensive Care Medicine 19, S54-S57.
32. Russell-Jones DL, Umpleby AM, Hennessy TR, Bowes SB, Shojaee-Moradie F, Hopkins KD, Jackson NC, Kelly JM, Jones RH & Sonksen P (1994) Use of a leucine clamp to demonstrate that IGF-I actively stimulates protein synthesis in normal humans. American Journal of Physiology 267, E591-E598.
33. Stathatos N, Levetan C, Burman KD & Wartofsky L (2001) The controversy of the treatment of critically ill patients with thyroid hormone. Best Practise Research in Clinical Endocrinology and Metabolism 15, 465-478.
34. Stewart P, Toogood A & Tomlinson J (2001) Growth hormone, insulin-like growth factor-I and the cortisol-cortisone shuttle. Hormone Research 56, 1-6.
35. Streat SJ, Beddoe AH & Hill GL (1987) Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. Journal of Trauma 27, 262-266.
36. Takala J, Ruokonen E, Webster NR, Nielsen MS, Zandstra DF, Vundelinckx G & Hinds CJ (1999) Increased mortality associated with growth hormone treatment in critically ill adults. New England Journal of Medicine 341, 785-792.
37. Unneberg K, Balteskard L, Mjaaland M & Revhaug A (1996) Growth hormone impaired compensation of hemorrhagic shock after trauma and sepsis in swine. Journal of Trauma 41, 775-780.
38. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY, Iranmanesh A, Veldhuis JD & Bouillon R (2002) The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone. Clinical Endocrinology 56, 655-669.
39. Van den Berghe G, Baxter RC, Weekers F, Wouters P, Bowers CY & Veldhuis JD (2000) A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. Journal of Clinical Endocrinology and Metabolism 85, 183-192.
40. Van den Berghe G & de Zegher F (1996) Anterior pituitary function during critical illness and dopamine treatment. Critical Care Medicine 24, 1580-1590.
41. Van den Berghe G, de Zegher F & Bouillon R (1998) Acute and prolonged critical illness as different neuroendocrine paradigms. Journal of Clinical Endocrinology and Metabolism 83, 1827-1834.
42. Van den Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Vlasselaers D, Schetz M, Verwaest C, Lauwers P & Bouillon R (1996) Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotrophin-releasing hormone in critical illness. Clinical Endocrinology 45, 341-351.
43. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Awouters M, Verbruggen W, Schetz M, Verwaest C, Lauwers P, Bouillon R & Bowers CY (1997a). The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. Journal of Clinical Endocrinology and Metabolism 82, 590-599.
44. Van den Berghe G, de Zegher F, Veldhuis JD, Wouters P, Gouwy S, Stockman W, Weekers F, Schetz M, Lauwers P, Bouillon R & Bowers CY (1997b) Thyrotrophin and prolactin release in prolonged critical illness: dynamics of spontaneous secretion and effects of growth hormone-secretagogues. Clinical Endocrinology 47, 599-612.
45. Van den Berghe G, Weekers F, Baxter RC, Wouters P, Iranmanesh A, Bouillon R & Veldhuis JD (2001a) Five-day pulsatile gonadotropin-releasing hormone administration unveils combined hypothalamic-pituitary-gonadal defects underlying profound hypoandrogenism in men with prolonged critical illness. Journal of Clinical Endocrinology and Metabolism 86, 3217-3226.
46. Van den Berghe G, Wouters P, Weekers F, Mohan S, Baxter RC, Veldhuis JD, Bowers CY & Bouillon R (1999) Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. Journal of Clinical Endocrinology and Metabolism 84, 1311-1323.
47. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P & Bouillon R (2001b) Intensive insulin therapy in the critically ill patients. New England Journal of Medicine 345, 1359-1367.
48. Vara-Thorbeck R, Guerrero JA, Ruiz-Requena ME, Capitan J, Rodriguez M, Rosell J, Mekinassi K, Maldonado M & Martin R (1992) Effects of growth hormone in patients receiving total parenteral nutrition following major gastrointestinal surgery. Hepatogastroenterology 39, 270-272.
49. Wang C, Chan V & Yeung RT (1978) Effect of surgical stress on pituitary-testicular function. Clinical Endocrinology 9, 255-266.
50. Weekers F, Michalaki M, Coopmans W, Van Herck E, Veldhuis JD, Darras VM & Van den Berghe G (2004) Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone and insulin infusion in a rabbit model of prolonged critical illness. Endocrinology 145, 205-213.
51. Weekers F, Van Herck E, Coopmans W, Michalaki M, Bowers CY, Veldhuis JD & Van den Berghe G (2002) A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response. Endocrinology 143, 764-774.
52. Youn Y, Suh G, Jung S, Oh S & Demling R (1998) Recombinant human growth hormone decreases lung and liver tissue lipid peroxidation and increases antioxidant activity after thermal injury. Journal of Burn Care and Rehabilitation 19, 542-548.